

Financial news for LXRX dated on 2020-05-13: Lexicon Pharma Highlights Will Present Preclinical Efficacy Data On Telotristat Ethyl's Antiproliferative Effects Against Various Cancer Cell Lines

Financial news for LXRX dated on 2020-04-28: Citigroup Maintains Neutral on Lexicon Pharmaceuticals, Lowers Price Target to \$2.1

Financial news for LXRX dated on 2020-04-28: 96 Biggest Movers From Yesterday

Financial news for LXRX dated on 2020-04-27: 72 Stocks Moving In Monday's Mid-Day Session

Financial news for LXRX dated on 2020-04-27: Lexicon Pharmaceuticals shares higher after the company reported better-than-expected Q1 EPS and sales results.

Financial news for LXRX dated on 2020-04-27: Lexicon Pharmaceuticals: Q1 Earnings Insights

Financial news for LXRX dated on 2020-04-27: Lexicon Pharmaceuticals Q1 EPS \$(0.63) Beats \$(0.69) Estimate, Sales \$7.999M Beat \$7.790M Estimate

Financial news for LXRX dated on 2020-04-26: The Week Ahead In Biotech (April 26-May 2): Cancer Conference, Earnings News Flow In The Spotlight

Financial news for LXRX dated on 2020-03-20: The Daily Biotech Pulse: Mylan Ramps Up Manufacturing Of Potential COVID-19 Drug, Lexicon Stops Study Early, Masimo To Buy German Ventilation Company

Financial news for LXRX dated on 2020-03-19: Lexicon Pharmaceuticals To Close Out Early Two Long-Term Outcome Studies Of Sotagliflozin Based On 'assessment that a near-term partnership sufficient to fund the studies to completion is now unlikely' As Well As Coronavirus Uncertainty

Financial news for LXRX dated on 2020-03-13: Lexicon Pharma Reports Added Data On Telotristat Ethyl's Antiproliferative Effects In Patients With Carcinoid Syndrome

Financial news for LXRX dated on 2020-03-12: Lexicon Pharmaceuticals: Q4 Earnings Insights

Financial news for LXRX dated on 2020-03-12: The Daily Biotech Pulse: AstraZeneca Faces Setback In Ovarian Cancer Study, Mallinckrodt To Explore COVID-19 Treatment, Imara IPO

Financial news for LXRX dated on 2020-03-12: Lexicon Pharmaceuticals Q4 EPS \$(0.48) Beats \$(0.77) Estimate, Sales \$8.727M Miss \$10.26M Estimate

Financial news for LXRX dated on 2020-03-08: The Week Ahead In Biotech (March 8-14): Bristol-Myers Awaits FDA Nod For Liver Cancer Combo Therapy, Earnings Flow Continues

Financial news for LXRX dated on 2020-01-23: 15 Biotechnology Stocks Moving In Thursday's After-Market Session

Financial news for LXRX dated on 2020-01-23: 20 Healthcare Stocks Moving In Thursday's After-Market Session

Financial news for LXRX dated on 2020-01-23: 146 Biotechnology Stocks Moving In Thursday's Session

Financial news for LXRX dated on 2020-01-22: 26 Biotechnology Stocks Moving In Wednesday's After-Market Session

Financial news for LXRX dated on 2020-01-22: 36 Healthcare Stocks Moving In Wednesday's After-Market Session

Financial news for LXRX dated on 2020-01-22: 98 Biotechnology Stocks Moving In Wednesday's Session

Financial news for LXRX dated on 2020-01-22: 116 Healthcare Stocks Moving In Wednesday's Session

Financial news for LXRX dated on 2020-01-20: Lexicon Pharmaceuticals Announces Poster Presentation at the ASCO 2020 Gastrointestinal Cancers Symposium

Financial news for LXRX dated on 2020-01-16: Lexicon Pharma 8-K Shows Co.'s Lex-Gen Woodlands Subsidiary Agreed To Sell Facilities In The Woodlands, Texas For \$15M

Financial news for LXRX dated on 2019-12-20: 28 Healthcare Stocks Moving In Friday's Pre-Market Session

Financial news for LXRX dated on 2019-12-20: Lexicon Pharma Reports Topline Phase 3 Data For Sotagliflozin In Type 2 Diabetes: Met Primary Endpoint

Financial news for LXRX dated on 2019-12-11: Benzinga's Top Upgrades, Downgrades For December 11, 2019

Financial news for LXRX dated on 2019-12-11: Gabelli & Co. Downgrades Lexicon Pharmaceuticals to Hold

Financial news for LXRX dated on 2019-12-09: 74 Biggest Movers From Friday

Financial news for LXRX dated on 2019-12-06: 55 Stocks Moving In Friday's Mid-Day Session

Financial news for LXRX dated on 2019-12-06: Lexicon Pharmaceuticals shares are trading higher on continued momentum after the company reported the topline Phase 1 data for its LX9211. NOTE: The study showed favorable safety results.

Financial news for LXRX dated on 2019-12-06: 75 Biggest Movers From Yesterday

Financial news for LXRX dated on 2019-12-05: Lexicon Pharmaceuticals shares are trading higher after the company reported the topline Phase 1 data for its LX9211. NOTE: The study showed favorable safety results.

Financial news for LXRX dated on 2019-12-05: Lexicon Pharma Reports Topline Phase 1 Data For LX9211: Shows Favorable Safety, Pharmacokinetics Profile Supportive Of Once-Daily Dosing

Financial news for LXRX dated on 2019-12-05: 72 Biggest Movers From Yesterday

Financial news for LXRX dated on 2019-12-04: Lexicon Pharmaceuticals shares are trading higher on continued momentum after the company announced it completed the initial stage for its Phase 2 clinical study of TELE-ABC.

Financial news for LXRX dated on 2019-12-03: Lexicon Pharmaceuticals Completes Safety Review Of Initial Safety Run-In Cohort Of TELE-ABC Phase 2 Clinical Study Of Telotristat Ethyl In Biliary Tract Cancer

Financial news for LXRX dated on 2019-12-03: 75 Biggest Movers From Yesterday

Financial news for LXRX dated on 2019-12-02: 44 Stocks Moving In Monday's Mid-Day Session

Financial news for LXRX dated on 2019-12-02: Why Lexicon Pharma Shares Are Moving Lower

Financial news for LXRX dated on 2019-12-02: Lexicon Pharmaceuticals shares are trading lower after the FDA reiterated its prior decision and denied Lexicon's appeal of the complete response letter for its Sotagliflozin.

Financial news for LXRX dated on 2019-12-02: Lexicon Pharma's Appeal of the FDA's Complete Response Letter for Sotagliflozin is Denied

Financial news for LXRX dated on 2019-11-20: Lexicon Pharmaceuticals shares are trading higher. Not currently seeing any company-specific news.

Financial news for LXRX dated on 2019-11-08: Benzinga's Top Upgrades, Downgrades For November 8, 2019

Financial news for LXRX dated on 2019-11-08: Lexicon Pharmaceuticals shares are trading lower after Citigroup downgraded the stock from Buy to Neutral.

Financial news for LXRX dated on 2019-11-08: Citigroup Downgrades Lexicon Pharmaceuticals to Neutral, Raises Price Target to \$4

Financial news for LXRX dated on 2019-11-07: Lexicon Pharma Filing Shows Registration For \$150M Mixed Securities Offering

Financial news for LXRX dated on 2019-11-07: 23 Healthcare Stocks Moving In Thursday's Pre-Market Session

Financial news for LXRX dated on 2019-11-07: 30 Stocks Moving in Thursday's Pre-Market Session

Financial news for LXRX dated on 2019-11-07: The Daily Biotech Pulse: Obseva Sinks On Adverse Clinical Readout, BioNano Surges On Saphyr Adoption, 2 IPOs

Financial news for LXRX dated on 2019-11-07: Lexicon Pharmaceuticals Q3 EPS \$1.95 vs \$0.73 Estimate, Sales \$294.448M Up From \$6.856M YoY

Financial news for LXRX dated on 2019-10-25: Lexicon Pharmaceuticals shares are trading higher in sympathy with the overall market on optimism around the U.S.-China trade deal.

Financial news for LXRX dated on 2019-10-07: Lexicon Pharmaceuticals shares are trading higher. Not seeing any news to justify the price action.

Financial news for LXRX dated on 2019-10-01: 58 Biggest Movers From Yesterday

Financial news for LXRX dated on 2019-09-30: 31 Stocks Moving In Monday's Mid-Day Session

Financial news for LXRX dated on 2019-09-30: Lexicon Pharmaceuticals shares are trading lower, potentially following a bearish blog post alleging the company does not have enough cash to finish ongoing trials.

Financial news for LXRX dated on 2019-09-30: 18 Healthcare Stocks Moving In Monday's Pre-Market Session

Financial news for LXRX dated on 2019-09-26: 55 Biggest Movers From Yesterday

Financial news for LXRX dated on 2019-09-25: Lexicon Pharmaceuticals shares are trading higher. The stock appears to be rebounding following a potential sell-off. Not seeing any news to justify the price action

Financial news for LXRX dated on 2019-09-24: Top 10 Most Overbought Stocks Via Benzinga Pro's Screener Tool For Tue., September 24, 2019

Financial news for LXRX dated on 2019-09-24: Lexicon Pharmaceuticals shares are trading lower. This could potentially be profit taking from investors after the stock rallied approximately 123% over the past 30 days.

Financial news for LXRX dated on 2019-09-20: 15 Healthcare Stocks Moving In Friday's Pre-Market Session

Financial news for LXRX dated on 2019-09-20: 46 Biggest Movers From Yesterday

Financial news for LXRX dated on 2019-09-19: 32 Stocks Moving In Thursday's Mid-Day Session

Financial news for LXRX dated on 2019-09-19: Lexicon Pharmaceuticals shares are trading lower as traders potentially took profits after the stock increased roughly 50% since last week.

Financial news for LXRX dated on 2019-09-19: 18 Healthcare Stocks Moving In Thursday's Pre-Market Session

Financial news for LXRX dated on 2019-09-19: 52 Biggest Movers From Yesterday

Financial news for LXRX dated on 2019-09-18: Mid-Afternoon Market Update: Dow Falls Over 200 Points After Federal Reserve Lowers Interest Rates

Financial news for LXRX dated on 2019-09-18: 36 Stocks Moving In Wednesday's Mid-Day Session

Financial news for LXRX dated on 2019-09-18: Mid-Day Market Update: FedEx Falls Following Downbeat Q2 Results; SPI Energy Shares Jump

Financial news for LXRX dated on 2019-09-18: Mid-Morning Market Update: Markets Edge Lower; General Mills Posts Mixed Q1 Results

Financial news for LXRX dated on 2019-09-18: Lexicon Pharmaceuticals shares are trading higher after two company insiders bought shares totaling \$1.054 million. NOTE: When an insiders buy shares, the market may perceive it as a sign of confidence in the company's outlook.

Financial news for LXRX dated on 2019-09-17: Biotech Stock On The Radar: vTv Therapeutics' Diabetes Pipeline

Financial news for LXRX dated on 2019-09-17: Top 10 Most Overbought Stocks Via Benzinga Pro's Screener Tool For Tuesday, September 17, 2019

Financial news for LXRX dated on 2019-09-17: Lexicon Pharmaceuticals shares are trading higher on continued momentum from Thursday when the company gave insight into the cash it will receive for its Zynquista Diabetes Program. The stock has increased roughly 30% since the announcement.

Financial news for LXRX dated on 2019-09-17: The Daily Biotech Pulse: Acceleron

Shelves Muscular Dystrophy Drug Trial, Aclaris Aces Late-Stage Study

Financial news for LXRX dated on 2019-09-16: Lexicon Pharmaceuticals shares are trading higher on seemingly no company-specific news.

Financial news for LXRX dated on 2019-09-15: The Week Ahead In Biotech: Novo Nordisk And Merck Await FDA Rulings, 2 IPOs On Deck

Financial news for LXRX dated on 2019-09-13: 24 Healthcare Stocks Moving In Friday's Pre-Market Session

Financial news for LXRX dated on 2019-09-13: 58 Biggest Movers From Yesterday

Financial news for LXRX dated on 2019-09-12: 28 Healthcare Stocks Moving In Thursday's Pre-Market Session

Financial news for LXRX dated on 2019-09-12: 33 Stocks Moving in Thursday's Pre-Market Session

Financial news for LXRX dated on 2019-09-12: 71 Biggest Movers From Yesterday

Financial news for LXRX dated on 2019-09-11: Mid-Afternoon Market Update: Dow Rises Over 100 Points; Zscaler Shares Tumble On Weak Earnings Guidance

Financial news for LXRX dated on 2019-09-11: 48 Stocks Moving In Wednesday's Mid-Day Session

Financial news for LXRX dated on 2019-09-11: Mid-Day Market Update: Crude Oil Down Over 2%; T2 Biosystems Shares Spike Higher

Financial news for LXRX dated on 2019-09-11: Benzinga's Top Upgrades, Downgrades For September 11, 2019

Financial news for LXRX dated on 2019-09-11: Gabelli & Co. Upgrades Lexicon Pharmaceuticals to Buy

Financial news for LXRX dated on 2019-09-11: 25 Healthcare Stocks Moving In Wednesday's Pre-Market Session

Financial news for LXRX dated on 2019-09-11: 26 Stocks Moving in Wednesday's Pre-Market Session

Financial news for LXRX dated on 2019-09-11: Lexicon Pharmaceuticals shares are trading higher after the company announced the termination of its alliance and settlement with Sanofi. Sanofi must pay the company \$260 million.

Financial news for LXRX dated on 2019-09-11: The Daily Biotech Pulse: Lexicon Snaps Sanofi Diabetes Partnership With \$260M Settlement, Celyad Offering, Multiple Sclerosis Conference Gets Underway

Financial news for LXRX dated on 2019-09-10: Lexicon Pharma Shares Resume Trade, Up 35.5%

Financial news for LXRX dated on 2019-09-10: Lexicon Pharmaceuticals shares are trading higher after the company announced the termination of its alliance and settlement with Sanofi. Sanofi must pay the company \$260 million.

Financial news for LXRX dated on 2019-09-10: Lexicon Pharmaceuticals Announces Termination Of Alliance and Settlement With Sanofi; Sanofi To Pay Co. \$206M

Financial news for LXRX dated on 2019-08-21: 25 Healthcare Stocks Moving In Wednesday's Pre-Market Session

Financial news for LXRX dated on 2019-08-13: Top 10 Most Oversold Stocks Via Benzinga Pro's Radar Tool For Tue., August 13, 2019

Financial news for LXRX dated on 2019-08-12: Top 10 Most Oversold Stocks Via Benzinga Pro's Screener Tool For Wed., August 12, 2019

Financial news for LXRX dated on 2019-08-09: Top 10 Most Oversold Stocks Via Benzinga Pro's Screener Tool For Fri., August 09, 2019

Financial news for LXRX dated on 2019-08-09: Lexicon Pharmaceuticals shares are trading higher after the company announced positive cardiorenal results from a pooled analysis from the inTandem1 and inTandem2 studies of Zynquista in adults with type 1 diabetes.

Financial news for LXRX dated on 2019-08-09: 31 Healthcare Stocks Moving In Today's Pre-Market Session

Financial news for LXRX dated on 2019-08-08: 50 Healthcare Stocks Moving In Thursday's After-Market Session

Financial news for LXRX dated on 2019-08-08: Lexicon Pharma Highlights Publication Of Data For Zynquista On Cardiorenal Clinical Biomarkers In Adults With Type 1 Diabetes

Financial news for LXRX dated on 2019-08-07: 42 Healthcare Stocks Moving In Wednesday's After-Market Session

Financial news for LXRX dated on 2019-08-07: Top 10 Most Oversold Stocks Via Benzinga Pro's Screener Tool For Wed., August 7, 2019

Financial news for LXRX dated on 2019-08-06: 28 Healthcare Stocks Moving In Today's Pre-Market Session

Financial news for LXRX dated on 2019-08-03: The Week Ahead In Biotech: Focus On Earnings Deluge, Mid-Year Clinical Trial Readouts

Financial news for LXRX dated on 2019-08-02: 29 Healthcare Stocks Moving In Friday's After-Market Session

Financial news for LXRX dated on 2019-08-02: Top 10 Most Oversold Stocks Via Benzinga Pro's Screener Tool For Fri., August 2, 2019

Financial news for LXRX dated on 2019-08-02: Stocks That Set New 52-Week Lows Friday Morning

Financial news for LXRX dated on 2019-08-01: Stocks that Reached Yearly Lows Thursday Morning

Financial news for LXRX dated on 2019-08-01: The Daily Biotech Pulse: Exelixis Signs Cancer Drug Licensing Deal, Adamis Offering, Surmodics Surges On Earnings

Financial news for LXRX dated on 2019-07-31: New 52-Week Low Achievers For Wednesday Morning

Financial news for LXRX dated on 2019-07-31: 28 Healthcare Stocks Moving In Today's Pre-Market Session

Financial news for LXRX dated on 2019-07-31: Lexicon Pharmaceuticals Q2 EPS \$(0.22) Misses \$(0.08) Estimate, Sales \$9.7M Do Not Compare To \$28.52M Estimate

Financial news for LXRX dated on 2019-07-31: 28 Healthcare Stocks Moving In Tuesday's After-Market Session

Financial news for LXRX dated on 2019-07-30: Top 10 Most Oversold Stocks Via Benzinga Pro's Screener Tool For Tue., July 30, 2019

Financial news for LXRX dated on 2019-07-30: 10 Biggest Price Target Changes For Tuesday

Financial news for LXRX dated on 2019-07-30: Citigroup Maintains Buy on Lexicon Pharmaceuticals, Lowers Price Target to \$3

Financial news for LXRX dated on 2019-07-30: The Daily Biotech Pulse: European Cheer For Merck, Legal Victory For Coherus, Medpace Picks Up On Earnings

Financial news for LXRX dated on 2019-07-30: 54 Biggest Movers From Yesterday

Financial news for LXRX dated on 2019-07-29: Mid-Afternoon Market Update: Crude Oil Up Over 1%; Lexicon Pharmaceuticals Shares Plunge

Financial news for LXRX dated on 2019-07-29: 42 Stocks Moving In Monday's Mid-Day Session

Financial news for LXRX dated on 2019-07-29: Top 10 Most Oversold Stocks Via Benzinga Pro's Screener Tool For Mon., July 29, 2019

Financial news for LXRX dated on 2019-07-29: Mid-Day Market Update: On Deck Capital Falls On Downbeat Earnings; Medley Management Shares Jump

Financial news for LXRX dated on 2019-07-29: Mid-Morning Market Update: Markets Mostly Lower; Mylan, Pfizer's Upjohn To Merge

Financial news for LXRX dated on 2019-07-29: UPDATE: Stifel Downgrades Lexicon Pharmaceuticals To Hold, Lowers Target To \$4 As Firm Notes 'Sanofi's Planned Sotagliflozin Exodus & P3 T2D CKD Data Clouds Visibility & Thesis'

Financial news for LXRX dated on 2019-07-29: What Caused The Opening Gap In Lexicon?

Financial news for LXRX dated on 2019-07-29: Benzinga's Top Upgrades, Downgrades For July 29, 2019

Financial news for LXRX dated on 2019-07-29: 30 Healthcare Stocks Moving In Today's Pre-Market Session

Financial news for LXRX dated on 2019-07-29: 10 Biggest Price Target Changes For Monday

Financial news for LXRX dated on 2019-07-29: 35 Stocks Moving In Monday's Pre-Market Session

Financial news for LXRX dated on 2019-07-29: Lexicon Shares Fall 47% On Termination Of License Agreement With Sanofi

Financial news for LXRX dated on 2019-07-29: Lexicon Pharmaceuticals shares are trading lower after Sanofi terminated its Zynquista collaboration with the company.

Financial news for LXRX dated on 2019-07-29: Lexicon Shares Fall 52% on Termination of License Agreement with Sanofi

Financial news for LXRX dated on 2019-07-29: Lexicon Pharmaceuticals Received Written Notice from Sanofi Terminating the Collaboration and License Agreement for the Worldwide Development and Commercialization of the Company's Diabetes Drug Candidate Sotagliflozin

Financial news for LXRX dated on 2019-07-29: Stifel Nicolaus Downgrades Lexicon Pharmaceuticals to Hold, Lowers Price Target to \$4

Financial news for LXRX dated on 2019-07-29: 40 Healthcare Stocks Moving In Friday's After-Market Session

Financial news for LXRX dated on 2019-07-27: The Week Ahead In Biotech: Pending Clinical Readouts, Earnings Dominate

Financial news for LXRX dated on 2019-05-01: The Daily Biotech Pulse: Nabriva Stumbles At FDA Hurdle, Gilead CFO To Retire, Eisai Ends Collaboration With Purdue

Financial news for LXRX dated on 2019-04-29: 38 Stocks Moving In Monday's Mid-Day Session

Financial news for LXRX dated on 2019-04-29: Lexicon Pharmaceuticals shares are trading higher after the company disclosed that Zynquista was approved in the European Union for the treatment of adults with Type 1 diabetes.

Financial news for LXRX dated on 2019-04-29: 22 Stocks Moving In Monday's Pre-Market Session

Financial news for LXRX dated on 2019-04-29: A Peek Into The Markets: US Stock Futures Edge Lower; Alphabet Earnings In Focus

Financial news for LXRX dated on 2019-04-29: 8 Stocks To Watch For April 29, 2019

Financial news for LXRX dated on 2019-04-26: Lexicon Pharmaceuticals shares are trading higher after the company's Zynquista was approved in the European Union for the treatment of adults with Type 1 diabetes.

Financial news for LXRX dated on 2019-04-26: Sanofi And Lexicon Zynquista Now Approved In The European Union For Treatment Of Adults With Type 1 Diabetes

Financial news for LXRX dated on 2019-03-26: 52 Biggest Movers From Yesterday

Financial news for LXRX dated on 2019-03-25: 41 Stocks Moving In Monday's Mid-Day Session

Financial news for LXRX dated on 2019-03-25: Gabelli & Co. Upgrades Lexicon Pharmaceuticals to Hold

Financial news for LXRX dated on 2019-03-25: 60 Biggest Movers From Friday

Financial news for LXRX dated on 2019-03-22: Lexicon Pharmaceuticals shares are trading lower after the FDA issued a complete response letter to the company, informing it that the application for its Zynquista type 1 diabetes treatment cannot be approved in its current form.

Financial news for LXRX dated on 2019-03-22: Lexicon Pharma Halted Multiple Times on Volatility Following Announcement of CRL from FDA. Now at \$5.63, \$1.38 Off the Low

Financial news for LXRX dated on 2019-03-22: Lexicon Shares Resumed Trade, Immediately Halted On Circuit Breaker, Down 40%

Financial news for LXRX dated on 2019-03-22: Lexicon Pharmaceuticals Resumes Trade after Announcing CRL and Immediately Halted on a Circuit Breaker

Financial news for LXRX dated on 2019-03-22: Lexicon Pharma Shares Resume Trade, Down 41%

Financial news for LXRX dated on 2019-03-22: Lexicon Shares To Resume Trade At 2:45 p.m. EDT

Financial news for LXRX dated on 2019-03-22: Lexicon Reports FDA Issued Complete Response Letter For Zynquista

Financial news for LXRX dated on 2019-03-22: Lexicon Pharma Shares Were Halted For News Pending About 70 Mins Ago; Stock Remains Halted Ahead Of Expected FDA Verdict On Diabetes Candidate, Zynquista

Financial news for LXRX dated on 2019-03-16: The Week Ahead In Biotech: Conferences, PDUFA Dates, Clinical Trials And Earnings

Financial news for LXRX dated on 2019-03-15: Lexicon Pharmaceuticals Announces Dosing Of First Patient In TELE-ABC Study, A Phase 2a Clinical Study Of Telotristat Ethyl In Biliary Tract Cancer

Financial news for LXRX dated on 2019-03-14: Benzinga's Top Upgrades, Downgrades For March 14, 2019

Financial news for LXRX dated on 2019-03-14: Gabelli & Co. Downgrades Lexicon Pharmaceuticals to Sell

Financial news for LXRX dated on 2019-03-14: 68 Biggest Movers From Yesterday

Financial news for LXRX dated on 2019-03-13: 48 Stocks Moving In Wednesday's Mid-Day Session

Financial news for LXRX dated on 2019-03-13: Lexicon Pharmaceuticals shares are trading higher after the company reported better-than-expected Q4 EPS and sales results.

Financial news for LXRX dated on 2019-03-13: 40 Stocks Moving In Wednesday's Pre-Market Session

Financial news for LXRX dated on 2019-03-13: The Daily Biotech Pulse: Aeterna Zentaris Explores Options, Verastem Plunges On Weak Copiktra Sales, FDA Nod For Aerie

Financial news for LXRX dated on 2019-03-13: Lexicon Pharmaceuticals Q4 EPS \$(0.16) Beats \$(0.29) Estimate, Sales \$17.1M Beat \$13.33M Estimate

Financial news for LXRX dated on 2019-03-13: Earnings Scheduled For March 13, 2019

Financial news for LXRX dated on 2019-03-04: Attention Biotech Investors: Mark Your Calendar For These March PDUFA Dates

Financial news for LXRX dated on 2019-03-04: 81 Biggest Movers From Friday

Financial news for LXRX dated on 2019-03-01: Mid-Afternoon Market Update: Crude Oil Down 2.5%; Nutanix Shares Plunge On Weak Forecast

Financial news for LXRX dated on 2019-03-01: 64 Stocks Moving In Friday's Mid-Day Session

Financial news for LXRX dated on 2019-03-01: Shares of Lexicon Pharmaceuticals are trading higher after the CHMP recommended the company's Zynquista for the treatment of adults with type 1 diabetes.

Financial news for LXRX dated on 2019-03-01: CHMP Recommends Lexicon And Sanofi's Zynquista For The Treatment Of Adults With Type 1 Diabetes

Financial news for LXRX dated on 2019-01-25: The Daily Biotech Pulse: Intuitive Surgical Earnings, Corbus To Offer Shares, Eton In-Licenses Neurologic Drug

Financial news for LXRX dated on 2019-01-24: Stocks Which Set New 52-Week Low Yesterday, Jan. 24, 2019

Financial news for LXRX dated on 2019-01-24: The Daily Biotech Pulse: Partial Clinical Hold On Advaxis Cervical Cancer Drug, Ohr's Reverse Split, Ironwood Starts

Phase 1 Trial

Financial news for LXRX dated on 2019-01-24: 54 Biggest Movers From Yesterday

Financial news for LXRX dated on 2019-01-22: 52 Biggest Movers From Friday

Financial news for LXRX dated on 2019-01-18: 36 Stocks Moving In Friday's Mid-Day Session

Financial news for LXRX dated on 2019-01-18: The Daily Biotech Pulse: Regulatory Roadblock For Immunomedics, AdCom Split On Lexicon's Diabetes Drug

Financial news for LXRX dated on 2019-01-17: Sanofi and Lexicon's Oral Type 1 Diabetes Drug Gets an Evenly Split FDA Advisory Panel at 8 to 8

Financial news for LXRX dated on 2019-01-17: The Daily Biotech Pulse: FDA Panel Backs Amgen's Hypertension Drug, Adamis Allergy Drug Launched In US

Financial news for LXRX dated on 2019-01-17: Lexicon Pharmaceuticals Reports FDA Advisory Committee Will Meet Today At 8:00 a.m. ET To Review Sotagliflozin New Drug Application For Treatment Of Type 1 Diabetes

Financial news for LXRX dated on 2019-01-17: Lexicon Pharmaceuticals Shares Halted, News Pending

Financial news for LXRX dated on 2019-01-13: The Week Ahead In Biotech: Conferences, PDUFA Dates And Clinical Trials

Financial news for LXRX dated on 2018-12-31: Attention Biotech Investors: Mark Your Calendar For These January PDUFA Dates

Financial news for LXRX dated on 2018-12-23: The Week Ahead In Biotech: Focus Shifts To Year-End Clinical Trial Results

Financial news for LXRX dated on 2018-12-20: Lexicon Pharma Reports Topline Phase 1 Results For LX2761 In Diabetes

Financial news for LXRX dated on 2018-12-18: Lexicon Pharmaceuticals Announces Topline Clinical Data For LX9211; Data Shows LX9211 Was Well Tolerated And Met Primary Objectives, Demonstrating A 'Favorable' Safety And Tolerability Profile

Financial news for LXRX dated on 2018-12-10: Stocks Which Set New 52-Week Low The Last Trading Session, Fri., Dec. 7, 2018

Financial news for LXRX dated on 2018-11-29: Lexicon Pharmaceuticals Reports FDA Advisory Committee To Review Investigational Sotagliflozin As Potential Treatment For Type 1 Diabetes

Financial news for LXRX dated on 2018-11-29: Lexicon Pharma Reports FDA AdCom Panel Will Review Investigational Sotagliflozin As Potential Treatment For Type-1 Diabetes On Jan. 17, 2019

Financial news for LXRX dated on 2018-11-28: Stocks Which Set New 52-Week Low Yesterday Tues., Nov. 27, 2018

Financial news for LXRX dated on 2018-11-27: Stocks Which Set New 52-Week Low Yesterday, Mon., Nov. 26, 2018

Financial news for LXRX dated on 2018-11-01: Stocks Which Set New 52-Week Low Yesterday, October 31st

Financial news for LXRX dated on 2018-11-01: Lexicon Pharmaceuticals, Inc. Q3 EPS \$(0.26) Up From \$(0.29) YoY, Sales \$6.856M Down From \$26.942M YoY

Financial news for LXRX dated on 2018-11-01: The Daily Biotech Pulse: AbbVie's Leukemia Drug Trial Meets Endpoint, Denali Strikes Collaboration Deal

Financial news for LXRX dated on 2018-10-16: Lexicon Pharmaceuticals And Ipsen Biopharmaceuticals Announce Health Canada Approval Af XERMELO For Treatment Of Refractory Carcinoid Syndrome Diarrhea In Combination With Somatostatin Analog Therapy

Financial news for LXRX dated on 2018-09-23: The Week Ahead In Biotech: Conferences, PDUFA Dates, Clinical Trial Results And IPOs

Financial news for LXRX dated on 2018-09-16: The Week Ahead In Biotech (Sept. 16-22): Conferences, PDUFA Dates, Clinical Trial Results And IPOs

Financial news for LXRX dated on 2018-07-30: Lexicon Pharmaceuticals Q2 EPS \$(0.33)

Beats \$(0.34) Estimate, Sales \$13.75M Miss \$15.86M Estimate

Financial news for LXRX dated on 2018-07-28: The Week Ahead In Biotech: Conferences, PDUFA Dates, Earnings And IPOs

Financial news for LXRX dated on 2018-07-01: Insider Buys Of The Week: AbbVie, Energen, NuStar And More

Financial news for LXRX dated on 2018-06-25: Insider Buys Of The Week: DDR, Salesforce, Lexicon Pharma

Financial news for LXRX dated on 2018-06-24: Lexicon Pharmaceuticals Announces Positive 52-Week Results from Sotagliflozin inTandem1 Study Presented at #ADA2018, Published in Diabetes Care

Financial news for LXRX dated on 2018-06-23: Lexicon Pharmaceuticals Announces Positive 52-Week Results From Sotagliflozin inTandem2 Study Presented at ADA 2018 and Published in Diabetes Care

Financial news for LXRX dated on 2018-06-01: 58 Biggest Movers From Yesterday

Financial news for LXRX dated on 2018-05-22: Lexicon Pharma Shares Spike 3% Over Last Few Mins.; Wedbush Issued Mid-Day Note Raising Price Target On Stock From \$40 To \$42, Maintains Outperform Rating

Financial news for LXRX dated on 2018-05-03: Benzinga's Daily Biotech Pulse: Achaogen Slumps On Mixed FDA Panel Vote, Pacific Biosciences Sinks On Q1 Miss

Financial news for LXRX dated on 2018-05-03: Lexicon Pharmaceuticals Q1 EPS \$(0.40) Beats \$(0.43) Estimate, Sales \$25.21 Miss \$22.96M Estimate

Financial news for LXRX dated on 2018-04-29: The Week Ahead In Biotech: PDUFA Dates, Clinical Trials, Merck And Pfizer Earnings On Tap

Financial news for LXRX dated on 2018-03-29: Lexicon Pharmaceuticals Announces EMA Acceptance of Marketing Authorization Application for Sotagliflozin to Treat Adults With Type 1 Diabetes

Financial news for LXRX dated on 2018-03-26: 17 Stocks Moving In Monday's Pre-Market Session

Financial news for LXRX dated on 2018-03-26: Lexicon Pharmaceuticals Announces Regulatory Submissions to the FDA and European Medicines Agency for Sotagliflozin to Treat Adults With Type 1 Diabetes

Financial news for LXRX dated on 2018-02-23: Earlier Today, Needham Downgraded Lexicon From Buy to Hold

Financial news for LXRX dated on 2018-02-22: Lexicon Pharma Reports Q4 GAAP EPS \$(0.27) vs \$(0.31) In Same Qtr. Last Year, Sales \$33M vs \$30M Est.

Financial news for LXRX dated on 2018-02-15: 42 Biggest Movers From Yesterday

Financial news for LXRX dated on 2018-02-14: 36 Stocks Moving In Wednesday's Mid-Day Session

Financial news for LXRX dated on 2018-02-14: Benzinga's Top Upgrades, Downgrades For February 14, 2018

Financial news for LXRX dated on 2018-02-14: JP Morgan Downgrades Lexicon Pharmaceuticals to Underweight

Financial news for LXRX dated on 2017-12-05: Lexicon Pharmaceuticals Secures up to \$200M Non-Dilutive Term Loan Financing

Financial news for LXRX dated on 2017-11-16: Lexicon Pharma Option Alert: Jan 19 \$15 Puts Sweep (9) at the Ask: 500 @ \$4.701 vs 802 OI; Ref=\$10.24

Financial news for LXRX dated on 2017-11-08: Lexicon Pharmaceuticals Reports Q3 EPS \$(0.29) vs \$(0.36) Est., Sales \$26.94M vs \$27.96M Est.

Financial news for LXRX dated on 2017-09-19: Lexicon Pharma Reports European Commission Approved XERMELo For Treatment Of Carcinoid Syndrome Diarrhea In Combination With Somatostatin Analog Therapy

Financial news for LXRX dated on 2017-09-14: 12 Biggest Mid-Day Losers For Thursday

Financial news for LXRX dated on 2017-09-08: UPDATE: Lexicon Pharma Says 'Patients on sotagliflozin 400 mg spent 2.8 hours longer in target glucose range per day than

placebo'

Financial news for LXRX dated on 2017-09-08: Lexicon Pharma Offers Pooled Continuous Glucose Monitoring Data From Phase 3 inTandem1, inTandem2 Studies Of Sotagliflozin: Patients On 200mg Spent 1.3 Hours Longer In Target Glucose Range vs Placebo

Financial news for LXRX dated on 2017-08-15: Lexicon Pharma Announces Phase 3 Tandem2 Study of Sotagliflozin Met All Secondary Endpoints

Financial news for LXRX dated on 2017-08-01: Lexicon Pharmaceuticals Reports Q2 EPS \$(0.33) vs \$(0.44), Sales \$12.05M vs \$18.3M Est.

Financial news for LXRX dated on 2017-07-21: Lexicon Pharma Receives Positive Opinion for Xermelo from the EU Medicines Agency

Financial news for LXRX dated on 2017-07-12: Benzinga's Option Alert Recap From July 12

Financial news for LXRX dated on 2017-07-12: Lexicon Pharma Option Alert: Aug 18 \$15 Puts Sweep (19) at the Bid: 512 @ \$0.853 vs 226 OI; Ref=\$15.82

Financial news for LXRX dated on 2017-06-23: Watch These 8 Huge Call Purchases In Friday Trade

Financial news for LXRX dated on 2017-06-22: Benzinga's Option Alert Recap From June 22

Financial news for LXRX dated on 2017-06-22: Option Alert: Lexicon Pharma Aug 20.0 Calls Sweep: 602 @ Above Ask! \$1.095: 2716 traded vs 104 OI: Earnings 8/3 After Close (est) \$17.25 Ref

Financial news for LXRX dated on 2017-06-19: Lexicon Pharma's XERMELO Included as a Recommended Treatment Option in the National Comprehensive Cancer Network Guidelines

Financial news for LXRX dated on 2017-06-11: Lexicon Announces Sotagliflozin Data from Pivotal in Tandem1, Tandem2 Studies in Patients with Type 1 Diabetes Presented at ADA 2017

Financial news for LXRX dated on 2017-06-09: 15 Biggest Mid-Day Gainers For Friday

Financial news for LXRX dated on 2017-06-09: 20 Stocks Moving In Friday's Pre-Market Session

Financial news for LXRX dated on 2017-06-09: Lexicon Pharma Shares Resume Trading

Financial news for LXRX dated on 2017-06-09: Lexicon Pharmaceuticals to Resume at 7:30 AM ET

Financial news for LXRX dated on 2017-06-09: Lexicon Pharmaceuticals Reports 'Positive' TLexicon Pharmaceuticals Reports Positive Top-Line Results In Phase 3 inTandem3 Study For Sotagliflozin In Patients With Type 1 Diabetes

Financial news for LXRX dated on 2017-06-09: Lexicon Pharma Halted, News Pending

Financial news for LXRX dated on 2017-06-08: Watch These 5 Huge Call Purchases In Thursday Trade

Financial news for LXRX dated on 2017-06-07: Option Alert: Lexicon Pharma Jul 15.0 Calls: 3000 @ ASK \$1.45: 3000 traded vs 2420 OI: Earnings 8/3 After Close (est) \$14.91 Ref

Financial news for LXRX dated on 2017-06-02: Lexicon Pharma Spikes to High of \$15.48 on Volume; June \$15 Calls Active

Financial news for LXRX dated on 2017-05-11: Lexicon Pharmaceuticals Reports Additional Positive Data From Pivotal InTandem1 Phase 3 Study For Sotagliflozin

Financial news for LXRX dated on 2017-05-02: Lexicon Pharmaceuticals Reports Q1 EPS \$(0.33) vs \$(0.42) Est., Sales \$18.29M vs \$17.7M Est.

Financial news for LXRX dated on 2017-03-03: 15 Biggest Mid-Day Gainers For Friday

Financial news for LXRX dated on 2017-03-03: Mid-Morning Market Update: Markets Edge Lower; Big Lots Profit Beats Estimates

Financial news for LXRX dated on 2017-03-03: 22 Stocks Moving In Friday's Pre-Market Session

Financial news for LXRX dated on 2017-03-03: Lexicon Pharma Reports Q4 EPS \$(0.31) vs \$(0.52) Est., \$0.76 in Same Qtr. Last Year, Sales \$23M vs \$15.6M Est.

Financial news for LXRX dated on 2017-03-03: Earnings Scheduled For March 3, 2017

Financial news for LXRX dated on 2017-03-01: 25 Stocks Moving In Wednesday's Pre-Market Session

Financial news for LXRX dated on 2017-02-28: UPDATE: Lexicon Reports Xermelo Treatment Now Available by Prescription And Will Be In Select Specialty Pharmacies Beginning March 6th

Financial news for LXRX dated on 2017-02-28: FDA Approves Lexicon Drug XERMELO

Financial news for LXRX dated on 2017-02-28: Lexicon Pharma Shares Halted News Pending

Financial news for LXRX dated on 2017-02-27: Reminder: Lexicon Pharmaceuticals Telotristate Etiprate Under FDA Priority Review, PDUFA Date Tuesday, Feb. 28th

Financial news for LXRX dated on 2017-02-07: Your Guide To 2017's Emerging Pharmaceuticals Catalysts

Financial news for LXRX dated on 2017-02-06: FDA Watch: February's Notable PDUFA Dates

Financial news for LXRX dated on 2017-01-03: 13 Emerging Biotechs With Catalysts In 2017

Financial news for LXRX dated on 2016-12-21: 15 Biggest Mid-Day Losers For Wednesday

Financial news for LXRX dated on 2016-12-21: 20 Stocks Moving In Wednesday's Pre-Market Session

Financial news for LXRX dated on 2016-12-21: Lexicon Phase 3 Trial for Sotagliflozin Met Primary Endpoint

Financial news for LXRX dated on 2016-12-06: 18 Stocks Moving In Tuesday's Pre-Market Session

Financial news for LXRX dated on 2016-12-05: Lexicon Pharmaceuticals Down 16.2% After Hours On Disappointing Phase 2 Results

Financial news for LXRX dated on 2016-12-05: Lexicon Top-Line Phase 2 Results Not Shown To Be Statistically Significant

Financial news for LXRX dated on 2016-11-09: Mid-Morning Market Update: Markets Rise; Donald Trump Wins 2016 Presidential Election

Financial news for LXRX dated on 2016-11-07: Lexicon Pharmaceuticals Acquires Exclusive Rights To Development Candidate For Neuropathic Pain From Its Alliance With Bristol-Myers Squibb

Financial news for LXRX dated on 2016-11-01: Lexicon Pharmaceuticals, Inc. Shares Up ~7% Following Earlier Q3 Report: EPS \$(0.35) vs Est \$(0.49), Revenue \$27.72M vs Est 9.68M

Financial news for LXRX dated on 2016-10-25: Lexicon Reports Positive Top-Line Results In Phase 2 Dose-Ranging Study For Sotagliflozin In Patients With Type 1 Diabetes

Financial news for LXRX dated on 2016-10-07: Lexicon Pharma Offers 'A 2-Part Story With Upside Prospects'

Financial news for LXRX dated on 2016-10-07: H.C. Wainwright Initiates Coverage on Lexicon Pharmaceuticals at Buy, Announces \$26.00 PT

Financial news for LXRX dated on 2016-10-05: Lexicon Pharmaceuticals Reports Agreement To Buy Out Remaining Obligations To Symphony Icon For \$21.01M, Buyout To Replace Remaining Contingent Payments Of Up To \$29.55M

Financial news for LXRX dated on 2016-09-21: Option Alert: LXRX Jan 20 \$17.5 Puts at the bid: Volume of 500 @ 2.05 vs 49 Open Interest

Financial news for LXRX dated on 2016-09-15: 15 Stocks Moving In Thursday's Pre-Market Session

Financial news for LXRX dated on 2016-09-14: UPDATE: Lexicon Pharma Says PDUFA Date for Telotristat Extended from Nov. 30, 2016 to Feb. 28, 2017

Financial news for LXRX dated on 2016-09-14: Lexicon Pharma Reports Extension of PDUFA Date for Telotristat Etiprate for Treatment of Carcinoid Syndrome

Financial news for LXRX dated on 2016-09-12: 10 Stocks Which Rallied Three Days

Financial news for LXRX dated on 2016-09-09: Mid-Day Market Update: Dow Down Over 200 Points; Finisar Shares Surge Following Strong Results

Financial news for LXRX dated on 2016-09-09: Benzinga's Volume Movers

Financial news for LXRX dated on 2016-09-09: Stocks Hitting 52-Week Highs

Financial news for LXRX dated on 2016-09-09: Mid-Morning Market Update: Markets Open Lower; Kroger Lowers FY Forecast

Financial news for LXRX dated on 2016-09-09: 12 Stocks Moving In Friday's Pre-Market Session

Financial news for LXRX dated on 2016-09-09: Lexicon Announces First Successful Phase 3 Trial of an Oral Anti-diabetic for Type 1 Diabetes

Financial news for LXRX dated on 2016-08-04: Lexicon Pharmaceuticals Reports Q2 \$(0.37) vs. Est. \$(0.40)

Financial news for LXRX dated on 2016-08-02: Buy/High Risk Rating Given To Lexicon Pharmaceuticals By Citi Analysts

Financial news for LXRX dated on 2016-08-02: Citigroup Initiates Coverage on Lexicon Pharmaceuticals at Buy, Announces \$21.00 PT

Financial news for LXRX dated on 2016-07-18: Lexicon Announces Validation Of Marketing Authorization For Carcinoid Syndrome Treatment

Financial news for LXRX dated on 2016-05-31: Lexicon Reports FDA Priority Review Of New Drug Application For Telotristat Etiprate For The Treatment Of Carcinoid Syndrome

Financial news for LXRX dated on 2016-05-05: Cowen & Company Assumes Lexicon Pharmaceuticals at Market Perform

Financial news for LXRX dated on 2016-05-03: Lexicon Pharmaceuticals Reports Q1 EPS \$(0.34) vs. Est. \$(0.30), Rev. \$12.5M vs. Est. \$11.11M

Financial news for LXRX dated on 2016-03-30: Lexicon Submits NDA To FDA For Telotristat Etiprate For Carcinoid Syndrome Treatment

Financial news for LXRX dated on 2016-03-01: Lexicon Pharma Reports Q4 EPS \$0.76, Rev. \$127.28M

Financial news for LXRX dated on 2016-01-02: Every Biotech Catalyst Wedbush Is Watching In 2016

Financial news for LXRX dated on 2015-12-01: Telotristat Etiprate Achieves Positive Top-Line Results In Second Phase 3 Clinical Trial, Met Primary Endpoint

Financial news for LXRX dated on 2015-11-06: Mid-Morning Market Update: Markets Decline; Humana Earnings Beat Estimates

Financial news for LXRX dated on 2015-11-06: Morning Market Gainers

Financial news for LXRX dated on 2015-11-06: Lexicon Pharma Report Q3 Loss \$0.34 Vs Est Loss \$0.36

Financial news for LXRX dated on 2015-11-06: Sanofi, Lexicon to Collaborate on Sotagliflozin, a Potential Diabetes Treatment

Financial news for LXRX dated on 2015-10-28: Option Alert: \$LXRX Apr \$7.5 Put; 2500 Contracts @\$2.40; Now \$9.60

Financial news for LXRX dated on 2015-10-19: Wedbush's Moussatos Reiterates Outperform, \$19 Target on Lexicon Pharma as 'TELESTAR Patient Exit Interviews Suggests A Meaningful Improvement in Quality of Life...'

Financial news for LXRX dated on 2015-10-19: Cancer Patients Treated With Lexicon's Telotristat Etiprate Report Improved Function And Well-Being

Financial news for LXRX dated on 2015-10-09: Lexicon Announces Telotristat Etiprate Data To Be Presented At North American Neuroendocrine Tumor Society Annual Symposium

Financial news for LXRX dated on 2015-09-29: US Stock Futures Rise Ahead Of Housing, Consumer Confidence Data

Financial news for LXRX dated on 2015-09-29: Lexicon's Telotristat Etiprate Shows Clinical Benefit In Treating Carcinoid Syndrome In Cancer Patients When Added To Standard Of Care

Financial news for LXRX dated on 2015-09-23: Tuesday's After-Hours Movers: 10 Stocks Moving After The Bell

Financial news for LXRX dated on 2015-08-26: Lexicon Announces Telotristat Etiprate Data To Be Presented At European Cancer Congress

Financial news for LXRX dated on 2015-08-10: Benzinga's Top Downgrades

Financial news for LXRX dated on 2015-08-10: JP Morgan Downgrades Lexicon Pharmaceuticals to Neutral, Raises PT to \$14.00

Financial news for LXRX dated on 2015-08-07: Lexicon Pharma Pipeline Progress Comments

Financial news for LXRX dated on 2015-08-07: Lexicon Pharma Reports Q2 EPS \$(0.27) vs. Est. \$(0.32)

Financial news for LXRX dated on 2015-08-04: Mid-Morning Market Update: Markets Edge Higher; Coach Beats Q4 Expectations

Financial news for LXRX dated on 2015-08-03: Mid-Day Market Update: Monday's Top 10 Volume Stocks

Financial news for LXRX dated on 2015-08-03: Mid-Day Market Update: Monday's Movers, Greece's Stock Market Opens, Auto Sales Boom And More

Financial news for LXRX dated on 2015-08-03: Lexicon Pharma Shares Now Up 60+% to Over \$13.50 Following Earlier News TELESTAR Trial Met Primary Endpoint

Financial news for LXRX dated on 2015-08-03: Hearing Wedbush Raises PT on Lexicon to \$19

Financial news for LXRX dated on 2015-08-03: Benzinga's Volume Movers

Financial news for LXRX dated on 2015-08-03: Stocks Hitting 52-Week Highs

Financial news for LXRX dated on 2015-08-03: Morning Market Gainers

Financial news for LXRX dated on 2015-08-03: Benzinga's Top #PreMarket Gainers

Financial news for LXRX dated on 2015-08-03: US Stock Futures Flat Ahead Of Economic Data

Financial news for LXRX dated on 2015-08-03: Lexicon Pharmaceuticals +14% Premarket as TELESTAR Phase 3 Clinical Trial Met Primary Endpoint

Financial news for LXRX dated on 2015-08-03: Lexicon Pharmaceuticals Announces Pivotal TELESTAR Phase 3 Clinical Trial Met Primary Endpoint

Financial news for LXRX dated on 2015-07-06: Mid-Afternoon Market Update: Dow Dips Over 100 Points; Crude Oil Tumbles 5.5%

Financial news for LXRX dated on 2015-06-07: Lexicon Presents Sotagliflozin Manuscript at American Diabetes Association Diabetes Care Symposium

Financial news for LXRX dated on 2015-04-29: Lexicon Pharma Reports Q1 Loss of \$0.04/Share, Inline, Sales \$1.8M vs \$1.1M Est.

Financial news for LXRX dated on 2015-04-29: Lexicon Reports One For Seven Reverse Stock Split

Financial news for LXRX dated on 2015-04-20: Pharmacological Advancements in Neuroscience Drug Discovery & Pre-Clinical Studies for Fragile X Syndrome to Identify Drug Candidates for Autism Therapies Lead Biotech Sector Research

Financial news for LXRX dated on 2015-04-15: Lexicon Pharma, Bristol-Myers Squibb Choose Development Candidate for Neuropathic Pain in Neuroscience Drug Discovery and Development Alliance

Financial news for LXRX dated on 2015-04-13: Jefferies: 10 Buyout Targets To Own During The M&A Boom

Financial news for LXRX dated on 2015-03-25: Lexicon Pharmaceuticals Announces First Patient Screened In Crucial Phase 3 Clinical Trial Of Sotagliflozin

Financial news for LXRX dated on 2015-03-18: Lexicon, Ipsen Expand Licensing & Commercialization Agreement For Telotristat Etiprate To Canada

Financial news for LXRX dated on 2015-03-09: Lexicon Pharma Announces Closing of Enrollment in Pivotal Phase 3 Clinical Trial of Telotristat Etiprate

Financial news for LXRX dated on 2015-03-04: Morning Market Gainers

Financial news for LXRX dated on 2015-03-04: UPDATE: Lexicon Pharmaceuticals Shares Surge On Upbeat Q4 Results

Financial news for LXRX dated on 2015-03-04: Lexicon Pharma Q4 EPS \$0.00 vs -\$0.03, Revenue \$21.5M vs \$12M

Financial news for LXRX dated on 2015-03-04: Earnings Scheduled For March 4, 2015

Financial news for LXRX dated on 2015-02-23: Lexicon's VP, Chief Scientific Officer Brian Zambrowicz Leaves Company

Financial news for LXRX dated on 2015-01-13: Biotechs Presenting At The J.P. Morgan Healthcare Conference: Day 3

Financial news for LXRX dated on 2014-11-21: Stocks Hitting 52-Week Lows

Financial news for LXRX dated on 2014-11-21: US Stock Futures Rise Ahead Of Earnings

Financial news for LXRX dated on 2014-11-21: Lexicon Prices 49.751M Share Offering @\$1.005/Share

Financial news for LXRX dated on 2014-11-20: Mid-Afternoon Market Update: Best Buy Rises After Upbeat Results; GoPro Shares Slide

Financial news for LXRX dated on 2014-11-20: Mid-Day Losers From November 20: Lexicon Pharmaceuticals, GoPro, Donaldson Company, Keurig Green Mountain

Financial news for LXRX dated on 2014-11-20: Mid-Day Market Update: U.S. Stocks Turn Higher; Williams-Sonoma Shares Climb On Earnings Beat

Financial news for LXRX dated on 2014-11-20: Mid-Morning Market Update: Markets Mixed; Dollar Tree Posts Upbeat Earnings

Financial news for LXRX dated on 2014-11-20: Morning Market Losers

Financial news for LXRX dated on 2014-11-19: Lexicon Announces \$75M Proposed Convertible Senior Notes Offering

Financial news for LXRX dated on 2014-11-19: Lexicon Announces Proposed Common Stock Offering Of \$50M In Shares

Financial news for LXRX dated on 2014-11-05: Stifel Nicolaus Maintains Buy on Lexicon Pharmaceuticals, Inc., Lowers PT to \$3.50

Financial news for LXRX dated on 2014-11-04: Lexicon Pharmaceuticals, Inc. Reports Q3 EPS of \$(0.08) Which May Not Compare \$(0.05) Est; Revenue of \$400.0K Which May Not Compare \$140.0K Est

Financial news for LXRX dated on 2014-10-22: Lexicon, Ipsen Enter Ex-North America/Japan Licensing and Commercialization Agreement for Telotristat Etiprate

Financial news for LXRX dated on 2014-09-18: Nurix Appoints Arthur Sands As CEO

Financial news for LXRX dated on 2014-09-11: Lexicon Pharmaceuticals Spikes Higher After-Hours

Financial news for LXRX dated on 2014-09-11: Lexicon Announces A Publication In The American Diabetes Association's Journal, Diabetes Care

Financial news for LXRX dated on 2014-08-29: S-3 from Lexicon Pharma Shows Registration for \$150M Mixed Securities Shelf Offering

Financial news for LXRX dated on 2014-08-19: Benzinga's Top Downgrades

Financial news for LXRX dated on 2014-08-19: Gabelli Downgrades Lexicon Pharmaceuticals To Hold

Financial news for LXRX dated on 2014-08-19: Gabelli Downgrades Lexicon

Pharmaceuticals, Inc. to Hold

Financial news for LXRX dated on 2014-08-07: Lexicon Pharmaceuticals, Inc. Reports Q2 EPS of \$(0.05), Inline

Financial news for LXRX dated on 2014-07-09: FOMC To End QE In October; The Container Store Shares Slide

Financial news for LXRX dated on 2014-07-09: AeroVironment Surges On Upbeat Results; The Container Store Shares Slide

Financial news for LXRX dated on 2014-07-09: Markets Edge Higher; Alcoa Profit Beats Street View

Financial news for LXRX dated on 2014-07-09: Morning Market Movers

Financial news for LXRX dated on 2014-07-09: US Stock Futures Flat; All Eyes On Fed Minutes

Financial news for LXRX dated on 2014-07-09: Lexicon And JDRF Collaborate For Phase 2 Clinical Trial Of LX4211 In Type 1 Diabetes

Financial news for LXRX dated on 2014-07-07: Lexicon Announces Lonnel Coats President and CEO

Financial news for LXRX dated on 2014-07-07: 3 Small-Cap Biotechs That Institutions Are Loving

Financial news for LXRX dated on 2014-05-08: Lexicon Pharmaceuticals Reports Q1 EPS of \$(0.06) vs \$(0.05) Est; Revenue of \$300.0K vs \$120.0K Est

Financial news for LXRX dated on 2014-04-14: Mid-Morning Market Update: Markets Open Higher; Citigroup Results Beat Estimates

Financial news for LXRX dated on 2014-04-14: Morning Market Movers

Financial news for LXRX dated on 2014-04-14: US Stock Futures Flat; Citigroup Earnings In Focus

Financial news for LXRX dated on 2014-04-14: Lexicon Pharmaceuticals Announces LX4211 Achieves Positive Results In Type 1 Diabetes Clinical Trial

Financial news for LXRX dated on 2013-12-17: Lexicon Pharma Shares Up ~1.2% Following 1.72M Share Block Trade at \$1.70/Share

Financial news for LXRX dated on 2013-12-06: Benzinga's Top Initiations

Financial news for LXRX dated on 2013-12-06: UPDATE: Bank of America Initiates Underperform On Lexicon Pharmaceuticals, Says Asset Overvalued

Financial news for LXRX dated on 2013-12-06: Bank of America Initiates Coverage on Lexicon Pharmaceuticals, Inc. at Underperform, Announces \$1.50 PO

Financial news for LXRX dated on 2013-12-03: Benzinga's Top #PreMarket Losers

Financial news for LXRX dated on 2013-12-03: US Stock Futures Signal Lower Start On Wall Street

Financial news for LXRX dated on 2013-12-03: Lexicon Phase 2 Study Of LX1033 In IBS-d Shows Differences Between Placebo and LX1033 were Not Statistically Significant

Financial news for LXRX dated on 2013-11-25: Stocks to Watch for November 25, 2013

Financial news for LXRX dated on 2013-10-22: Top 4 Small-Cap Stocks In The Biotechnology Industry With The Lowest PEG Ratio

Financial news for LXRX dated on 2013-10-09: Wedbush's Moussatos Says Sees No 'Major Impact' Following News of Lower-Than-Expected Benefit from Pilot Study

Financial news for LXRX dated on 2013-10-09: Benzinga's Top Pre-Market Losers

Financial news for LXRX dated on 2013-10-09: Lexicon Pilot Study of Telotristat Etiprate In Ulcerative Colitis Achieves Primary Objective Demonstrating Safety, Tolerability

Financial news for LXRX dated on 2013-10-01: Market Wrap For Tuesday, October 1: Government Down, Markets Up

Financial news for LXRX dated on 2013-10-01: Mid-Afternoon Market Update: Markets

Remain Up As Government Shutdown Continues

Financial news for LXRX dated on 2013-10-01: Mid-Day Market Update: US Stocks Extend Gains; Lexicon Shares Surge

Financial news for LXRX dated on 2013-10-01: Mid-Morning Market Update: Markets Rise; Walgreen Earnings Surge 86%

Financial news for LXRX dated on 2013-10-01: Morning Market Movers

Financial news for LXRX dated on 2013-10-01: Benzinga's Top Pre-Market Gainers

Financial news for LXRX dated on 2013-10-01: Lexicon Pharma Reports Results from Trial of LX4211, Says Met Primary Goal, Says There Were No Serious Adverse Events

Financial news for LXRX dated on 2013-07-30: Lexicon Pharmaceuticals, Inc. Reports Q2 EPS of \$(0.06) vs \$(0.05) Est; Revenue of \$214.0K vs \$280.0K Est

Financial news for LXRX dated on 2013-07-30: Lexicon Pharmaceuticals Provides Clinical Pipeline Update

Financial news for LXRX dated on 2013-07-23: Market Wrap for Tuesday, July 23: Stocks Close Mixed as Investors Focus on Earnings

Financial news for LXRX dated on 2013-06-24: Lexicon Pharma Issues Preclinical Data on LX2761

Financial news for LXRX dated on 2013-06-11: UPDATE: Morgan Stanley Downgrades Lexicon Pharmaceuticals on Challenged Valuation

Financial news for LXRX dated on 2013-06-11: Morgan Stanley Downgrades Lexicon Pharmaceuticals, Inc. to Underweight, Lowers PT to \$1.50

Financial news for LXRX dated on 2013-05-30: UPDATE: Jefferies Initiates Lexicon Pharmaceuticals at Buy on Class-Leading SGLT Inhibitor

Financial news for LXRX dated on 2013-05-30: Jefferies Initiates Coverage on Lexicon Pharmaceuticals, Inc. at Buy, Announces \$3.50 PT

Financial news for LXRX dated on 2013-05-29: Jefferies Initiates Coverage on Lexicon Pharmaceuticals, Inc. at Buy, Announces \$3.50 PT

Financial news for LXRX dated on 2013-05-10: Lexicon Pharmaceuticals, Inc. Reports Q1 EPS of \$(0.05), Inline; Revenue of \$400.0K vs \$300.0K Est

Financial news for LXRX dated on 2013-05-10: Lexicon Issues Update on Phase 2 Trial of LX4211 In Type 1 Diabetes

Financial news for LXRX dated on 2013-04-29: Market Wrap for Monday, April 29: Stocks Start Week With a Rally

Financial news for LXRX dated on 2012-12-31: Stocks Surge as Fiscal Cliff Deal Appears Close

Financial news for LXRX dated on 2012-12-31: Mid-Day Market Update: Political Indecision Looms, Yet Markets Rise

Financial news for LXRX dated on 2012-12-31: Mid-Morning Market Update: Markets Rise Ahead of Fiscal Cliff, Cott Falls

Financial news for LXRX dated on 2012-12-17: Mid-Morning Market Update: Caribou Bought Out; Clearwire Plummets

Financial news for LXRX dated on 2012-12-17: Benzinga's Top Pre-Market Gainers

Financial news for LXRX dated on 2012-12-17: Lexicon Pharma Shares Rise Following FDA Fast Track Designation for LX1033 for IBS

Financial news for LXRX dated on 2012-11-06: Lexicon Pharma Says Primary Efficacy Endpoint Was Achieved

Financial news for LXRX dated on 2012-11-06: From Earlier: Lexicon Pharmaceuticals Reports Q3 EPS \$-0.06 vs \$-0.06 Est; Revenues \$372K vs \$600.00K Est

Financial news for LXRX dated on 2012-10-18: Lexicon Prices 17.5M Shares At \$2.25 per Share

Financial news for LXRX dated on 2012-10-17: Lexicon Announces Proposed Common Stock Offering

Financial news for LXRX dated on 2012-10-16: Benzinga's Top Pre-Market Gainers

Financial news for LXRX dated on 2012-10-12: Benzinga's Top Pre-Market Gainers

Financial news for LXRX dated on 2012-10-12: A Peek Into The Market Before The Trading Starts

Financial news for LXRX dated on 2012-10-12: Lexicon Pharmaceuticals Announces Phase 2 Trial Of Telotristat Etiprate Shows Positive Results In Carcinoid Syndrome

Financial news for LXRX dated on 2012-09-13: Gabelli & Company Initiates Coverage on Lexicon Pharmaceuticals at Buy

Financial news for LXRX dated on 2012-08-16: A Peek Into The Market Before The Trading Starts

Financial news for LXRX dated on 2012-08-16: Lexicon Pharmaceuticals Reports Preliminary Results From Two Phase 1 Studies

Financial news for LXRX dated on 2012-08-06: Benzinga's Top Pre-Market Gainers

Financial news for LXRX dated on 2012-07-31: Lexicon Pharmaceuticals Reports On Clinical Program Status And 2012 Second Quarter Results

Financial news for LXRX dated on 2012-06-29: A Peek Into The Market Before The Trading Starts

Financial news for LXRX dated on 2012-06-29: Lexicon Announces Publication of Results of Two Studies of LX4211 in Patients with Type 2 Diabetes in the Journal Clinical Pharmacology & Therapeutics

Financial news for LXRX dated on 2012-06-26: Lexicon Pharmaceuticals Soaring After Stifel Nicolaus Raises Price Target

Financial news for LXRX dated on 2012-06-26: UPDATE: Stifel Nicolaus Raises PT to \$4 on Lexicon Pharmaceuticals on LX4211 P2b Efficacy Data

Financial news for LXRX dated on 2012-06-26: Stifel Nicolaus Maintains Lexicon Pharmaceuticals at Buy, Raises PT from \$3 to \$4

Financial news for LXRX dated on 2012-06-25: Benzinga's Top Pre-Market Gainers

Financial news for LXRX dated on 2012-06-25: Lexicon Announces Positive Results of LX4211 Phase 2b Trial For Type 2 Diabetes

Financial news for LXRX dated on 2012-05-03: Lexicon Receives Funding for Phase 2 Clinical Trial of LX4211 in Type 1 Diabetes

Financial news for LXRX dated on 2012-01-09: LX4211 Enhances Effects of DPP-4 Inhibition in Patients with Type 2 Diabetes

Financial news for LXRX dated on 2011-12-12: Investor Ideas' Biotech/ Pharma Stocks To Watch: Friday's Gainers

Financial news for LXRX dated on 2011-11-22: A Peek Into The Market Before The Trading Starts

Financial news for LXRX dated on 2011-11-22: Lexicon Announces Commencement of Rights Offering to Stockholders

Financial news for LXRX dated on 2011-09-13: Lexicon Pharmaceuticals Announces LX4211 for Diabetes Shown to Reduce Fasting and Post-Prandial Blood Sugar in Healthy Subjects

Financial news for LXRX dated on 2011-08-10: Lexicon Announces Publication of Results From the Phase 2 Trial of LX1031 in Patients With Irritable Bowel Syndrome in Journal of Gastroenterology

Financial news for LXRX dated on 2011-08-09: Lexicon Pharmaceuticals Announces Phase 2 Trial of LX1032, Telotristat Etiprate, Shows Positive Results in Carcinoid Syndrome

Financial news for LXRX dated on 2011-08-09: Phase 2 Trial of Lexicon's LX1032, Telotristat Etiprate, Shows Positive Results in Carcinoid Syndrome

Financial news for LXRX dated on 2011-07-08: Lexicon Pharmaceuticals Crossed Below 200 Day Moving Average Of \$1.67

Financial news for LXRX dated on 2011-06-24: Lexicon Pharmaceuticals Trading Up Over

9% in Pre-Market

Financial news for LXRX dated on 2011-05-13: J.P. Morgan Maintains Overweight Rating on Lexicon Pharmaceuticals

Financial news for LXRX dated on 2011-01-10: Benzinga's Top Pre-Market NASDAQ Gainers (CNXT, GENZ, XING, LXRX)

Financial news for LXRX dated on 2011-01-06: Morning Market Movers (HAUP, LXRX, ANX, CAFI)

Financial news for LXRX dated on 2011-01-06: Benzinga's Top Pre-Market NASDAQ Gainers (LXRX, ARMH, MVIS, GOLD)

Financial news for LXRX dated on 2010-08-09: Lexicon Posts Narrower-Than-Expected Q2 Loss

Financial news for LXRX dated on 2010-03-21: How Will Obama-Care Play Into The Markets And ETFs?

Financial news for LXRX dated on 2010-03-08: Benzinga's News Roundup (LXRX, MET, AZN, BA)

Financial news for LXRX dated on 2010-01-21: Benzinga's Top Pre-Market Gainers (LXRX, STKL, STX, PLXS, DEAR, EBAY)

Financial news for LXRX dated on 2010-01-20: Benzinga's Top Pre-Market Gainers (DEER, LXRX, RMBS, SIRI, CREE, AIXG, DDSS)

Financial news for LXRX dated on 2009-10-09: Biggest Losers (SPPI, ACOR, LEAP, LXRX, CLRT)

Financial news for LXRX dated on 2009-10-08: Stocks to Watch (AA, HOTT, SVNT, SCSC, LXRX, BX)

Financial news for LXRX dated on 2009-09-16: Biggest Losers (AGCO, FNET, LXRX, DSCO, CGA)

Financial news for LXRX dated on 2009-09-15: Today's Morning Top Gainers (FNET, LXRX, DIET, CLFD, MPG, CVM)

Financial news for LXRX dated on 2009-09-15: New 52-Week High Stocks - LXRX, CLFD, CVM, AAPL, CRUS

Financial news for LXRX dated on 2009-09-15: Lexicon Pharmaceuticals (LXRX) Shares Doubles On Positive Early Trials